GSK R&D chief Hal Barron (left) and Vir CEO George Scangos
August 31, 2020 08:00 AM EDTUpdated 10:09 AM
R&D
Coronavirus

GSK, Vir bar­rel in­to a fast PhII/III for their lead Covid-19 an­ti­body, chas­ing a mov­ing tar­get with quick OK in sight

John Carroll

Editor & Founder

Now that Eli Lil­ly and Re­gen­eron have strayed off sched­ule on the de­vel­op­ment of new an­ti­bod­ies to fight Covid-19, Glax­o­SmithK­line ex­ecs and their part­ners at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times